Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands

The radionuclide therapy [<sup>177</sup>Lu]Lu-PSMA-617 was recently FDA-approved for treatment of metastatic castration-resistant prostate cancer. Salivary gland toxicity is currently considered as the main dose-limiting side effect. However, its uptake and retention mechanisms in the sa...

Full description

Bibliographic Details
Main Authors:	Nathalie Heynickx, Charlotte Segers, Amelie Coolkens, Sarah Baatout, Koen Vermeulen
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	Pharmaceuticals
Subjects:	PSMA targeted radionuclide therapy prostate cancer salivary gland toxicity
Online Access:	https://www.mdpi.com/1424-8247/16/5/692

Similar Items

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023-05-01)

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis
by: Wolfgang Roll, et al.
Published: (2021-07-01)

Comparative Analysis of Morphological and Functional Effects of <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands
by: Benedikt Feuerecker, et al.
Published: (2023-11-01)

Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with <sup>177</sup>Lu-PSMA and Combined <sup>225</sup>Ac- and <sup>177</sup>Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation
by: Thomas Langbein, et al.
Published: (2022-08-01)

First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
by: Thomas J. W. Klein Nulent, et al.
Published: (2021-12-01)

Improved quality control of [177Lu]Lu-PSMA I&T
by: Martin Kraihammer, et al.
Published: (2023-03-01)

Single Center Experience with a 4-Week <sup>177</sup>Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Jukka Kemppainen, et al.
Published: (2022-12-01)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022-10-01)

Tubarial salivary glands on PSMA ligands based PET imaging and post 177Lu PSMA therapy scan: reiterating its importance
by: Srinivas Kumar, et al.
Published: (2024-01-01)

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

Impact of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [<sup>68</sup>Ga]Ga-PSMA-11-PET/CT
by: Daniel Groener, et al.
Published: (2023-07-01)

Baseline [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT before [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
by: Daniel Groener, et al.
Published: (2023-01-01)

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Dheeratama Siripongsatian, et al.

Renal Safety of [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function
by: Florian Rosar, et al.
Published: (2021-06-01)

The effect of eating on the uptake of PSMA ligands in the salivary glands
by: V. Mohan, et al.
Published: (2021-09-01)

Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management
by: Sonia Mahajan, et al.
Published: (2022-07-01)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022-03-01)

Intermittent Radioligand Therapy with <sup>177</sup>Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
by: Nicolai Mader, et al.
Published: (2023-09-01)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022-10-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

Early PSA Change after [<sup>177</sup>Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival
by: Felix Kind, et al.
Published: (2021-12-01)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021-05-01)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [<sup>177</sup>Lu]Lu-PSMA I&T
by: Philipp E. Hartrampf, et al.
Published: (2022-01-01)

Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
by: Florian Rosar, et al.
Published: (2021-05-01)

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
by: V. Mohan, et al.
Published: (2021-03-01)

Value of Combined PET Imaging with [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [<sup>177</sup>Lu]Lu-PSMA-617 RLT
by: Fadi Khreish, et al.
Published: (2021-08-01)

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
by: Yasemin Sanli, et al.
Published: (2021-04-01)

Quality Assurance Investigations and Impurity Characterization during Upscaling of [<sup>177</sup>Lu]Lu-PSMA<sup>I&T</sup>
by: Stefan Schmitl, et al.
Published: (2023-11-01)

Prognostic Value of the De Ritis Ratio for Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy
by: Sebastian Gaal, et al.
Published: (2023-10-01)

Outcome of <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer
by: Nicolai Mader, et al.
Published: (2021-08-01)

Salvage Radioligand Therapy with Repeated Cycles of <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement
by: Daniel Groener, et al.
Published: (2021-08-01)

Radiobiological Assessment of Targeted Radionuclide Therapy with [<sup>177</sup>Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models
by: Julia Raitanen, et al.
Published: (2023-11-01)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
by: Frederik A. Verburg, et al.
Published: (2023-11-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Dosimetry of <sup>177</sup>Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol
by: Anna Sarnelli, et al.
Published: (2019-02-01)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under <sup>177</sup>Lu-PSMA-617 Radioligand Therapy
by: Liam Widjaja, et al.
Published: (2021-06-01)

Production and Quality Control of [<sup>177</sup>Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
by: Valentina Di Iorio, et al.
Published: (2022-06-01)

Streamlined Schemes for Dosimetry of <sup>177</sup>Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
by: Jens Kurth, et al.
Published: (2021-08-01)

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA
by: LUO Tian-wei, et al.
Published: (2023-12-01)

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience
by: Florian Rosar, et al.
Published: (2022-05-01)